News

Reynolds (NASDAQ:REYN) Posts Q1 Sales In Line With Estimates

Household products company Reynolds (NASDAQ:REYN) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.8% year on year to $818 million. On the other hand, next quarter’s revenue guidance of $897.5 million was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.23 per share was in line with analysts’ consensus estimates.

Vita Coco (NASDAQ:COCO) Surprises With Strong Q1

Coconut water company The Vita Coco Company (NASDAQ:COCO) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 17.2% year on year to $130.9 million. On the other hand, the company’s full-year revenue guidance of $562.5 million at the midpoint came in 1.2% below analysts’ estimates. Its GAAP profit of $0.31 per share was 61.9% above analysts’ consensus estimates.

Morning Bid: U.S. economy creaking even before tariffs

There is growing evidence the U.S. economy was struggling even before this month's tariff sweep, ramping up the chances of a 2025 recession and bets that the Federal Reserve will eventually cut interest rates as much as four times this year. * The U.S. economy likely stalled or even contracted in the first quarter, underscoring the disruptive nature of President Donald Trump's often chaotic tariff policy. * President Donald Trump signed a pair of orders to soften the blow of his auto tariffs on Tuesday, and his trade team touted its first deal with a foreign trading partner.

Wabash (NYSE:WNC) Misses Q1 Revenue Estimates, Stock Drops 12.9%

Semi trailers and liquid transportation container manufacturer Wabash (NYSE:WNC) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 26.1% year on year to $380.9 million. The company’s full-year revenue guidance of $1.8 billion at the midpoint came in 3.9% below analysts’ estimates. Its non-GAAP loss of $0.58 per share was significantly below analysts’ consensus estimates.

United Therapeutics (NASDAQ:UTHR) Reports Bullish Q1

Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 17.2% year on year to $794.4 million. Its GAAP profit of $6.63 per share was 5.1% above analysts’ consensus estimates.